A similar trend was observed for almost all of the scenarios evaluated in Table 1. The magnitude of the differences in fa, as a result of changing SCH772984 cell line krel, was higher for highly permeable compounds (BCS classes 1 and 2). On the contrary, FG showed an opposite trend as compared to that of fa. The CR formulations showed higher FG than their IR counterparts, the increase

was inversely related to the decrease in drug release rate. The magnitude of the increase in FG was dependent on the CLint,CYP3A4 and was typically observed for virtual compounds with CLint,CYP3A4 equal to or greater than 200 μL/min/mg. For compounds displaying a low affinity to CYP3A4, the differences in FG were almost imperceptible ( Figs. 3B and S1B–S2B). On the contrary, for compounds with high affinity for CYP3A4, the difference in FG as a function of both release rate and CLint,CYP3A4 was highly marked (scenario IIb; Fig. S3B). For the simulated P-gp substrates (scenarios IIIa and IIIb in Table 1) the relationship between AUC and drug release was similar to that observed for the CYP3A4 substrates. Nevertheless, irrespectively of the values for CLint,P-gp, the AUC decreased as the release rate was reduced, this was more pronounced for low soluble compounds (BCS classes 2 and 4; Figs. 4A and S4A). For BCS class 1 compounds,

CLint,P-gp values between 0.007 and 30 μL/min had almost no impact on the AUC. However, a decrease in the AUC was observed when CLint,P-gp Linifanib (ABT-869) was set to 300 μL/min (Figs. 4A and S4A). No Selleckchem Autophagy inhibitor differences were noticeable when fixing either Jmax,P-gp or Km,P-gp. As for the CYP3A4 substrates, the fa was

lower for CR formulations than for their IR counterparts, and decreased as the release rate decreased. On the contrary to what was seen for CYP3A4 substrates, altering CLint,P-gp had an impact on the fa, where the impact on fa was dependent upon the CLint,P-gp values and BCS classification. The fa of BCS class 2 compounds was the most sensitive to changes in CLint,P-gp ( Figs. 4B and S4B). Since the aforementioned compounds were not subject to metabolism, neither the release rate nor the CLint,P-gp had an impact on FG. Scenarios IVa–Vb in Table 1 describe the simulations carried out for virtual compounds with overlapped affinity for both CYP3A4 and P-gp. When CLint,CYP3A4 was varied, and using a fixed CLint,P-gp (2 μL/min), no significant differences were observed between the new AUC trend compared to the trend observed for CYP3A4 substrates only (Figs. 5A and S5A). A similar outcome was obtained when the analysis was performed from the P-gp point of view, i.e., varying CLint,P-gp and using a fixed CLint,CYP3A4 (2500 μL/min/mg); the observed trends were similar to that for P-gp substrates alone (Figs. S6–7B). Likewise, both fa and FG followed almost a similar pattern as the observed for CYP3A4 or P-gp substrates only ( Figs. 5B and S5–7B).